EKF Diagnostics Holdings PLC Director/PDMR Shareholding (3216Z)
January 11 2024 - 2:00AM
UK Regulatory
TIDMEKF
RNS Number : 3216Z
EKF Diagnostics Holdings PLC
11 January 2024
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
PDMR/Director Dealings
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business, announces that t he Board of EKF has been
informed that on Tuesday 9 January 2024, certain funds connected to
Christopher Mills, Non-Executive Director, purchased a total of
100,000 ordinary shares of 1 pence each in the Company ("Ordinary
Shares") at a price of 30 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and
indirect interest in the Company is 132,250,000 Ordinary Shares,
representing approximately 29.147% of the total voting rights over
the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK
MAR is set out below as is the Standard form for notification of
major holdings received by EKF today.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Harwood Capital LLP and Harwood Capital
Management (Gibraltar) Ltd, (the "Investment
Managers")
--------------------------------------- ----------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------------
a) Position/status Christopher Mills is the Non-Executive
Director of the issuer and Chief Executive
of the Investment Managers
--------------------------------------- ----------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------------
a) Name EKF Diagnostics Holdings plc
--------------------------------------- ----------------------------------------------------
b) LEI 213800DXTF3EAUK1AR05
--------------------------------------- ----------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 pence each
financial instrument,
type of instrument
Identification code GB0031509804
b) Nature of the transaction Purchase of Ordinary Shares
--------------------------------------- ----------------------------------------------------
c) Price(s) and volume(s)
----------------------- ------------------------
Price(s) Volume(s)
----------------------- ------------------------
0.30 100,000
----------------------- ------------------------
d) Aggregated information
- Aggregated volume N/A single transaction
- Price
e) Date of the transaction 9 January 2024
--------------------------------------- ----------------------------------------------------
f) Place of the transaction London Stock Exchange, AIMX
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Julian Baines, Executive Chair Tel: +44 (0)29 2071 0570
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Oliver Platts
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804
654
About EKF Life Sciences
EKF Life Sciences is a specialist global manufacturer of
high-quality enzymes and custom products for use in diagnostic,
pharmaceutical, and industrial applications.
EKF Life Sciences is at the forefront of supporting global
demand in precision fermentation, enzyme applications and research,
providing innovative biotechnology solutions to deliver
advancements in healthcare and medicine.
Utilising its unique technical expertise, the EKF Life Sciences
uses precision microbial fermentation and advanced downstream
processes to isolate and deliver the highest quality enzymes and
biomolecules that have been specially engineered to customer
specifications.
EKF Life Sciences has two state-of-the-art GMP manufacturing
facilities, located within close proximity, in Elkhart and South
Bend Indiana, one the US's major life sciences and industrial
hotspots. It operates to the highest regulatory standards under
cGMP principles, FDA certification and ISO 13485 Quality Program.
The facilities include bioreactors ranging from 5L to 14,500L,
enabling it to offer an end-to-end service from
bench/proof-of-concept through to full scale commercial production,
providing its customers with desired yields, precision at scale and
cost-efficiency.
EKF Lifesciences is also one of the market leaders for the
supply of <BETA>-HB, a reagent used to detect ketones for
patients suffering from diabetic ketoacidosis, as well as many
other clinical applications.
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is an AIM-listed global diagnostics business focussed
on:
-- Point-of-Care analysers in the key areas of Hematology and
Diabetes, as well as Central Laboratory products including clinical
chemistry reagents, analysers and centrifuges.
-- Life Sciences services provide specialist manufacture of
enzymes and custom products for use in diagnostic, food and
industrial applications, as well as other higher value Contract
Manufacturing services.
EKF has headquarters in Penarth (near Cardiff) and operates five
manufacturing sites across the US and Germany, selling into over
120 countries world-wide.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDDGDBRXBDGSG
(END) Dow Jones Newswires
January 11, 2024 02:00 ET (07:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Oct 2024 to Nov 2024
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Nov 2023 to Nov 2024
